Virtual Library

Start Your Search

Vladmir Claudio Cordeiro De Lima



Author of

  • +

    P04 - Early Stage/Localized Disease - Perioperative Therapy (Neoadjuvant Therapy, Surgery, Adjuvant Therapy) (ID 113)

    • Event: WCLC 2020
    • Type: Posters
    • Track: Early Stage/Localized Disease
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      P04.01 - Adjuvant Chemotherapy is not Associated with Worse Disease-Free Survival in the Elderly Population.   (ID 3211)

      00:00 - 00:00  |  Author(s): Vladmir Claudio Cordeiro De Lima

      • Abstract
      • Slides

      Introduction

      Adjuvant chemotherapy after complete surgical resection is currently the standard of care for patients with stage IB-IIIA (7th Ed. TNM) non-small-cell lung cancer. The applicability of this treatment to the elderly population however is not completely established. This retrospective study evaluated the indication of adjuvant treatment and the influence of age on survival in patients over 65 years with stage I-III non-small-cell lung cancer.

      Methods

      We analyzed 177 patients with resectable stage I-III non-small-cell lung cancer who underwent standard lung cancer surgery between 2005 and 2019 at A. C. Camargo Cancer Center, São Paulo, Brazil. Patients were divided in two age groups: <65 years-old and ≥65 years-old years. Indication of chemotherapy by age group and the influence of age on survival were studied. We used descriptive statistics (median and frequencies) to characterize the population. Frequencies were compared by the Pearson’s Chi-squared or Fisher’s exact test. Kaplan-Meier method was used to calculate survival curves. Overall survival (OS) was defined as the time in months from the date of surgery to the date of death by any cause. Survival curves were compared by the log-rank test. Disease-free survival (DFS) was defined as the time in months from the date of surgery to the date of disease relapse, diagnosis of second neoplasia or death by any cause. A p-value<0.05 was considered statistically significant for all tests.

      Results

      40.7% patients were older than 65 years. Median age at diagnosis was 72 years among the elderly and 55 years in the younger group. 15.8% were stage IB, 23.7% stage II and 21.5% stage IIIA. The majority of patients (55.9%) had ECOG 0 and 65% had a Charlson’s comorbidity score of 3 to 5. The elderly had statistically more comorbidities when compared to the young group (40.1% x 64.2%, p=0.0005). 38.4% of patients received adjuvant chemotherapy after surgery with no statistical difference between the two groups (53.1% x 41.9%, p=0.12). With a medium follow-up of 48.13 months, OS was significantly shorter in the elderly population (55.5mo x 39.2mo; 95%CI 41.09-55.16; p=0.002), nevertheless DFS did not differ significantly between groups (15.6mo x 15.3mo; 95%CI 12.7-17.8; p=0.93). Furthermore, when analyzed according to number of comorbidities, OS was significantly shorter in the group with ≥2 comorbidities (p=0.04).

      Conclusion

      Age was not employed as the sole criteria to withheld adjuvant chemotherapy in our center. Most of patients had multiple comorbidities and the elderly had considerably more. Despite the lower OS among the elderly, our data showed similar DFS, suggesting there is an excess of death in this group due to non-cancer related causes.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P09 - Health Services Research/Health Economics - Real World Outcomes (ID 121)

    • Event: WCLC 2020
    • Type: Posters
    • Track: Health Services Research/Health Economics
    • Presentations: 4
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      P09.06 - CNS Metastasis Negatively Impact Overall Survival of Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Immune Checkpoint Inhibitors.  (ID 3314)

      00:00 - 00:00  |  Author(s): Vladmir Claudio Cordeiro De Lima

      • Abstract
      • Slides

      Introduction

      Lung cancer is the leading cause of cancer‐related death worldwide. Unfortunately, most of patients are diagnosed with advanced NSCLC. Stage, performance status and central nervous system (CNS) metastases have been recognized as prognostic factors. Immune checkpoint inhibitors (ICI) have greatly improved survival outcomes and can result in deep and durable antitumor responses in lung cancer but survival rates vary among patients with metastatic disease.

      Methods

      We retrospectively collected data from patients diagnosed with NSCLC from 2005 to 2019 at A. C. Camargo Cancer Center, São Paulo, Brazil, and treated with ICIs. Demographics and clinical characteristics were described as medians and frequencies. Overall survival (OS) was defined as the time from the date of diagnosis to the occurrence of death by any cause. Survival curves were calculated by Kaplan-Meier method and compared by the log-rank test. Univariate and multivariate Cox proportional hazards models were used to estimate hazard ratios (HR). All tests were considered statistically significant when p<0.05.

      Results

      A total of 81 patients were included in the final analysis. Median age was 62 (36-91) years; 54% were men and the majority of patients (75%) had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Approximately 67% were previous/current smokers and median tobacco consumption was 31 packs-year. Median Charlson Comorbidity Index (CCI) was 7. The majority of patients had lung adenocarcinomas (72%). More than half of patients (53%) had multiple sites of metastases. Eighteen (22%) patients had CNS metastasis. The median follow-up was 38.7 months and the estimated median OS was 29.5 months (CI 95%, 18.3 – 40.8) for patients treated with ICIs. Having multiple metastases was associated with inferior survival compared with ≤1 site of metastasis (median 14.8 vs. 121.0 months; p<0.001). Longer OS was observed in patients with ECOG PS 0 or 1 compared to those with ECOG PS ≥2 (median 29.6 vs. 14.8 months; p=0.02). CCI>7 (p<0.001). Regarding site of metastasis, median OS was significantly lower in patients presenting with CNS metastases (8.0 vs 30.4 months; HR 2.85; p<0.001). Gender and histological subtypes were not associated with OS. In multivariate analysis, CNS metastases (HR 2.27; p=0.028), ECOG PS≥2 (HR 2.47; p=0.02), multiple organ metastases (HR 3.32; p=0.002) and CCI>7 (HR 2.68; p=0.017) retained independent adverse prognostic impact.

      Conclusion

      Immunotherapeutic agents represent a new treatment strategy for lung cancer but their efficacy on patients with CNS metastases is still unknown and these patients are largely excluded from clinical trials. Therefore, CNS metastases remain a critical issue in the management of patients affected by lung cancer since they confer a poor prognosis and the treatment options are limited. Moreover, in our study, the number of metastatic sites and having more than one associated comorbidity were also correlated with survival in this population.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

    • +

      P09.09 - Overall Survival in Elderly Metastatic Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade (ID 3483)

      00:00 - 00:00  |  Author(s): Vladmir Claudio Cordeiro De Lima

      • Abstract
      • Slides

      Introduction

      Lung cancer is the leading cause of cancer death. Despite the high frequency of lung cancer among the elderly (patients ≥65 years-old), this population is underrepresented in clinical trials, including, though to a lesser extent, those investigating immunotherapy. The objective of this study was to describe the clinical-pathological profile of metastatic Non-Small Cell Lung Cancer (NSCLC) patients treated with immune checkpoint blockade (ICB) and analyze the overall survival (OS) according to age. We also compared the OS of metastatic elderly patients treated or not with ICB.

      Methods

      This was a retrospective cohort that included all metastatic NSCLC patients, diagnosed from August 1999 to December 2019, treated with ICB or other therapies at A. C. Camargo Cancer Center, São Paulo, Brazil. Demographics and clinical-pathological data were collected from electronic medical records. The variables evaluated were age, gender, race, smoking status, Charlson score, ECOG, histology, presence of EGFR or ALK driver mutations, number of metastasis sites and number of treatment lines. OS for patients treated with ICB as first, second or third line of therapy was evaluated according to age: ≥65 years-old (elderly) or <65 years-old (young patients). We used descriptive statistics (median and frequencies) to characterize the population. Frequencies were compared by Pearson’s Chi-squared or Fisher’s exact test. OS was defined as the time between the date of diagnosis to the date of death by any cause. Kaplan-Meyer method was used to estimate survival curves. Survival between groups was compared by the log-rank test. Tests with p<0.05 were considered statistically significant.

      Results

      Among the 81 patients that used ICB, 40.7% were ≥65yo, 54.3% were men, 79.1% were white and 54.3% were former smokers. 34.6% of all patients had a Charlson’s comorbidity score 7 or 8. 75.3% had ECOG 0-1 and 71.6% had adenocarcinomas. 44% had EGFR mutations or ALK rearrangements, 49.4% had 1 to 2 metastatic sites and 58.9% received up to 3 treatment lines. Clinical characteristics distribution among 471 patients not treated with ICB were similar to that observed in the population treated with ICB, except for the frequency of EGFR mutations and ALK rearrangements (65.6%), of patients with 1 to 2 metastatic sites (66.8%), and of patients who received up to 3 treatment lines (80.9%). At a median follow-up of 38.7 months for the population who used ICB, median OS was 29,5 months (95%CI 18.29-40.77). Median OS was 29.63 months for the elderly versus 28.87 months for the young patients (p=0.92). No difference was observed using 70yo as a cutoff, as well (p=0.63). For comparison, OS among elderly patients who were not treated with ICB was 21.22 months.

      Conclusion

      The elderly seems to derive the same benefit from ICB as younger patients. OS among elderly patients that received ICB was longer than among those who were not treated with ICB.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

    • +

      P09.41 - Body Mass Index (BMI) Is Associated With Overall Survival in Patients With Metastatic Non-Small Cell Lung Cancer (ID 2268)

      00:00 - 00:00  |  Author(s): Vladmir Claudio Cordeiro De Lima

      • Abstract
      • Slides

      Introduction

      Obesity is related to increased mortality in several types of tumors, including endometrium, postmenopausal breast cancer and bladder. Contradictorily, for lung cancer there seems to be an inverse relationship, and patients with higher body mass index (BMI), obese or overweight, have improved survival.

      BMI is the ratio between the weight in kilograms and the height in meters squared and is commonly used as surrogate for body composition. Using the BMI, obesity is defined as a BMI ≥30 Kg/m2, of overweight as a BMI between 25 and 29,9 Kg/m², normal weight as a BMI from 18,5 to 24,9 Kg/m² and underweight below 18,5 Kg/m2.

      The objective of this study was to analyze the BMI of the patients with Non-Small Cell Lung Cancer (NSCLC) and to investigate its impact on overall survival.

      Methods

      We conducted a retrospective analysis of patients diagnosed with metastatic non-small cell lung cancer diagnosed between 2000 and 2019, at AC Camargo Cancer Center, Brazil. Demographics, clinical-pathological characteristics, treatment patterns and outcomes data were obtained from electronic medical records.

      We collected weight and height information to calculate the BMI. Other variables such as ECOG, Charlson’s comorbidity score, histological subtype, smoking load and number of metastasis were also analyzed. Overall survival was defined as the time between diagnosis and death by any cause. We used descriptive statistics to characterize the study population. Association between BMI and other variables was tested with Pearson’s Chi-Squared or Fisher’s exact tests. The Kaplan-Meyer method was used to estimate survival. Impact of BMI on survival was calculated with Cox regression method. P-values <0.05 were considered statistically significant.

      Results

      We analyzed data from 456 patients with metastatic NSCLC. About 52,9% were men, 73,9% were white, 21,9% were smokers, 42,1% were former smokers and 32,2% non-smokers. Most of the patients had adenocarcinoma (78,5%). 63,2% of patients had ≥2 sites of metastasis. Median Charlson’s score was 8 and 46,7% had ECOG 1.

      Median BMI was 24,3 kg/m2 (13,0-50,8). Patients were dichotomized into two groups based on the median BMI: <24,3 (89,7%) and ≥ 24,3 (10,3%).

      At a median follow up of 41,5 months, the median overall survival of the group who had lower BMI was 15,8 months versus 24,3 months in the group with higher BMI (HR=1,56; 95% IC 1,0-2,3; P-value=0,034).

      Conclusion

      According to our data, there is an inverse relation between BMI and risk of death in patients with metastatic NSCLC. Patients who had lower BMI had a worse overall survival. BMI is associated with survival and should be considered as a prognostic factor in patients with lung cancer.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

    • +

      P09.43 - Familial History of Cancer and Overall Survival in NSCLC Patients. (ID 1994)

      00:00 - 00:00  |  Author(s): Vladmir Claudio Cordeiro De Lima

      • Abstract
      • Slides

      Introduction

      Lung cancer is the most common cancer worldwide and has high rates of mortality. It is estimated that individuals with any familial history of lung cancer were more than twice as likely to be diagnosed with lung cancer as were those without familial history. A better understanding of how familial history of lung cancer and of cancer in general affects prognosis of NSCLC patients may be important for the development of personalized screening, diagnosis and treatment.

      Methods

      This retrospective cohort included NSCLC patients diagnosed at A. C. Camargo Cancer Center, São Paulo, Brazil, from 2000 to 2019, for whom we were able to recover information regarding familial history of cancer. Information regarding demographics, clinical characteristics and familial history of lung cancer and of cancer in general was recovered from medical records and summarized using descriptive statistics (medians and frequencies). Overall survival (OS) was defined as the time between the data of diagnosis and the date of death by any cause. The Kaplan-Meier method was employed to estimate survival curves. Univariate Cox model was used to compare survival between groups. Tests were considered statistically significant when p<0.05.

      Results

      Among the 642 patients included, 53.3% were male and 40.3% were white. Median age in the whole population was 63 years old. Globally, 77.9% had ECOG 0-1 and 68.1% were current or ex-smokers. The predominant histology was non-squamous NSCLC, representing 83.6% of patients. Driver genes most frequently altered were EGFR (24.9%), ALK (3.0%) and KRAS (4.4%). Most patients were diagnosed in stages IV (55.3%) and III (23,8%), according to the 8th edition of AJCC. Among 287 stage I-III patients, 70% had a first-degree relative diagnosed with cancer. We observed a significant difference in OS between patients with and without familial history of cancer (median OS: 12,8 months x not reached; p=0,021). 13,6% of patients had familial history of lung cancer. We did not observe a significant difference in OS between patients with and without lung cancer familial history (p=0,997). Among 355 stage IV patients, 66,8% had a first-degree relative diagnosed with any cancer and 16,9% had familial history of lung cancer. We did not observe a significant difference in the median OS between patients with and without familial history of (p=0,759) or lung cancer (p=0,139).

      Conclusion

      Familial history of cancer was associated with shorter OS, nevertheless effect was observed among non-metastatic NSCLC lung cancer patients only. On the other hand, OS was not associated with familial history of lung cancer.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P18 - Locoregional and Oligometastatic Disease - Misc. Topics (ID 128)

    • Event: WCLC 2020
    • Type: Posters
    • Track: Locoregional and Oligometastatic Disease
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      P18.06 - Retrospective Epidemiological Study of Locally Advanced Non-Small Cell Lung Cancer Patients in Brazil – RELANCE (LACOG 0118) (ID 2892)

      00:00 - 00:00  |  Presenting Author(s): Vladmir Claudio Cordeiro De Lima

      • Abstract
      • Slides

      Introduction

      Lung cancer represents an important public health problem in Brazil. Despite suboptimal registry, it is estimated that lung cancer accounted for 28,220 new cases in Brazil in 2016. Nonetheless, there is limited data regarding stage distribution, patterns of treatment and outcomes of NSCLC in Brazil. Around 20-35% of NSCLC patients have stage III at diagnosis. Due to its heterogeneous nature, patients can be amenable to different therapeutic strategies such as upfront surgery, chemoradiation, systemic treatment or palliative care only. Importantly, multidisciplinary team discussion and planning of treatment impacts patients’ outcomes. Little information is available on how stage III NSCLC is treated in clinical practice in Brazil. The RELANCE study aims to capture real world data on stage III NSCLC and to identify possible gaps to achieve optimal treatment for this population in Brazil.

      Methods

      LACOG 0118 RELANCE is a large multi-institutional study that will collect information regarding sociodemographic data, diagnostic tests, treatment and outcome of patients diagnosed with locally advanced (clinical stage IIIA, IIIB and IIIC) NSCLC in Brazil in the period of January 2015 to June 2019.

      Socio-demographic characteristics, clinicopathological features, treatment patterns and outcomes will be extracted from medical charts. Disease status and survival data will be collected up to the last date of follow-up June 2021.

      Primary endpoint is to describe overall survival (OS) of locally advanced stage III NSCLC in Brazil. Descriptive analysis of treatments and outcomes are planned. Multivariate analysis will be used in order to identify prognostic factors for survival using the Cox regression. The expected target sample size is 400 patients with locally advanced NSCLC.

      Results

      As of 25th July, 42 patients have been included, all of them within 6 Brazilians sites. Currently, there are 6 sites awaiting regulatory approval to start enrollment. Recruitment is planned to last until December 2020 when the estimated sample size will be achieved.

      Conclusion

      LACOG 0118 RELANCE study is one of the largest patient registry that will evaluate current clinical practice for stage III NSCLC in Brazil. The study will describe potential gaps to optimal treatment and demographic and socioeconomic factors associated with patient outcome.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P19 - Locoregional and Oligometastatic Disease - Oligometastatic Disease (ID 129)

    • Event: WCLC 2020
    • Type: Posters
    • Track: Locoregional and Oligometastatic Disease
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      P19.12 - Immunotherapy as Single Treatment for Brain Metastases of Non-small cell Lung Cancer: A Systematic Review and Meta-Analysis.  (ID 3511)

      00:00 - 00:00  |  Author(s): Vladmir Claudio Cordeiro De Lima

      • Abstract
      • Presentation

      Introduction

      Brain metastases (BM) occur in approximately 40% of lung cancer patients along the course of their disease. Immunotherapy has changed the treatment landscape of non-small cell lung cancer (NSCLC) without an actionable driver gene mutation. Its activity in patients with BM, however, remains controversial, as the cornerstone treatment in this scenario is local treatment, especially radiotherapy (RDT). Since RDT is associated with adverse events that may impair quality of life, the possibility of substituting it by a single systemic approach is very attractive. Therefore, we performed a systematic review and meta-analysis to evaluate the potential benefit of immune checkpoint inhibitors (ICIs) in NSCLC patients with untreated BM (unBM).

      Methods

      Studies that enrolled NSCLC patients treated with ICIs and allowed for unBM, published or presented as abstracts in congresses or meetings from inception to April 2020 were identified by searching the Embase, PubMed, LILACS, Scopus and Cochrane Library databases. The outcomes evaluated were intracerebral overall response rate (ORR) and intracerebral disease control rate (iDCR) for unBM, as well as grades 3/4 toxicity rate and the rate of progression free survival (PFS) in 6 months, calculated through the inverse variance random-effect method for single arm. We also compared ORR and iDCR between patients with treated and untreated BM, using pooled risk ratios with the random effect model.

      Results

      We included 12 studies, n=566 individuals, in the final analysis. All patients were treated with anti-PD1 therapy. Most patients had adenocarcinoma histology and a good performance status; were current or former smokers; had up to 5 brain lesions and were asymptomatic from the BM. Anti-PD1 therapy appears to be active in the central nervous system, with a median ORR of 13.4% (95% IC 7.1% - 20.8%, p = 0.272) and a median iDCR of 38.3% (95% IC 27.1% - 50.1%, p = 0.195), with acceptable grades 3/4 toxicity rate (median value of 18.9%; 95% IC 10.1% – 29.2%; p = 0.767). In the meta-analysis for ORR (HR = 1.26, 95% IC: 0.57 - 2.79; p = 0.58) and iDCR (HR = 0.88, 95% IC: 0.55 - 1.43; p = 0.58) we did not observe any difference between patients with BM who were treated with RDT prior to ICI start and those who were treated with ICI only. Median PFS for unBM ranged from 1.1 to 2.3 months. PFS rate in 6 months was 30.4% (95% IC 22.9% – 38.6%, p< 0.001), with a high heterogeneity (I² = 85.41%).

      Conclusion

      ICIs appear to be effective as a single treatment for active BM in selected patients with advanced NSCLC. This approach not only delays side effects related to radiotherapy, but also allows for a sooner systemic management. Results from ongoing trials will help to more definitely clarify the role of immunotherapy in this scenario and who are the patients that will benefit the most.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

  • +

    P33 - Pathology - Immunotherapy Biomarker (ID 101)

    • Event: WCLC 2020
    • Type: Posters
    • Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      P33.19 - Association Between Expression of Immune Response-Related Genes and Response to Nivolumab in Metastatic Non-Small Cell Lung Cancer (ID 3572)

      00:00 - 00:00  |  Author(s): Vladmir Claudio Cordeiro De Lima

      • Abstract
      • Slides

      Introduction

      Immune checkpoints inhibitors (ICIs) have provided long durable responses in many tumor types, including non-small cell lung cancer (NSCLC). Unfortunately, most patients do not benefit from ICI therapy and, eventually, adverse events can be severe. Therefore, biomarkers to identify patients most likely to benefit from immunotherapy are urgently needed.

      To identify a gene expression profile associated with tumor response and clinical outcomes in a cohort of patients with metastatic NSCLC treated with nivolumab in second or further lines of therapy.

      Methods

      Thirty metastatic NSCLC patients treated with nivolumab in second or later lines at A. C. Camargo Cancer Center, São Paulo, Brazil, from 2015 to 2017 were included. Twenty patients have been previously included in an expanded access program of nivolumab (BMS CA 209-169). Baseline (before ICI) archival FFPE samples were obtained and RNA was extracted. The expression of 41 genes involved with immune response (CCL2, CCL3, CCL4, CCL5, CCL19, CCL21, CD274, CD3D, CD3Z, CD8A, CXCL9, CXCL10, CXCL11, CXCL13, CXCR6, EOMES, FOXP3, GZMA, GZMB, HLA-DRA1, HLAE-DRA1, IFNG, IL10, IRF1, IRF3, IRF7, LAG3, MAVS, NKG7, PDCD1, PFR1, PTPRC, RIG1, STAT1, TBET, GATA3, TBX21, TGFB, TIGIT, STING, TNFA) was analyzed by RT-qPCR in a Taq-Man Low-Density Array platform. Demographic data and treatment outcomes were collected retrospectively from medical records. Treatment response was assessed by RECIST 1.1 and patients were categorized as achieving clinical benefit (CB) [complete response (CR), partial response (PR) or stable disease (SD) ≥6 months] or disease progression (DP) [SD <6 months or DP]. Response to treatment was correlated with expression of each isolated gene using the two-sided Wilcoxon test, area under the curve (AUC) and logistic regression. Analyses of overall survival (OS) and progression-free survival (PFS) were performed using Cox regression.

      Results

      In this cohort, the median age at onset of nivolumab was 58.5 years. Fifteen patients (50%) were male, 80% had good performance status (ECOG 0-1), 63.3% had metastatic disease at diagnosis and 76.6% were smokers or former smokers. Adenocarcinoma was the most common histology (80%), and only 4 patients had a driver mutation detected. Nivolumab was administered as second or third line of treatment in 73% of cases. After a median follow-up of 43 months, the median PFS was 2.2 months (95% CI, 0.0-4.86) and the median OS was 16.4 months (95% CI, 10.6-22.3). The CB rate was 36.7%. Gene expression of CCL3, LAG3, IL10, FOXP3, PTPRC, CCL5, IFNG, NKG7, IRF1 and CXCL9 was associated with CB (p<0.05). Among these genes, we chose that better predicted CB (AUC>0.7) and combined them to generate a gene expression signature. The signature score predicted CB with an AUC of 0.81 (p=0.01). Additionally, patients with a high signature score presented significantly improved PFS (HR 0.11, p=0.0003) and OS (HR 0.30, p=0.029).

      Conclusion

      In this small cohort of NSCLC patients treated with nivolumab in second or later lines, survival was similar to that previously reported for nivolumab as second line in the literature. We were able to identify a gene expression signature associated with tumor response, PFS and OS.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.